Page 64 - Programme book for The International Liver Congress 2015, EASL ILC 2015

THURSDAY, APRIL 23, 2015

General Session 1 & Opening Ceremony Hall D

Chairs:
Serge Erlinger, France
Markus Peck-Radosavljevic, Austria

SCIENTIFIC PROGRAMME 13:30 - 14:00 Opening Ceremony
ABSTRACT
G01 LIRAGLUTIDE IS EFFECTIVE IN THE HISTOLOGICAL
14:00 - 14:15 CLEARANCE OF NON-ALCOHOLIC STEATOHEPATITIS
IN A MULTICENTRE, DOUBLE-BLINDED, RANDOMISED,
ABSTRACT PLACEBO-CONTROLLED PHASE II TRIAL
G02 Matthew J. Armstrong, The United Kingdom
14:15 - 14:30
LEDIPASVIR/SOFOSBUVIR WITH RIBAVIRIN IS SAFE AND
ABSTRACT EFFICACIOUS IN DECOMPENSATED AND POST LIVER
G03 TRANSPLANTATION PATIENTS WITH HCV INFECTION:
14:30 - 14:45 PRELIMINARY RESULTS OF THE PROSPECTIVE SOLAR 2
TRIAL
ABSTRACT Michael Manns, Germany
G04
14:45 - 15:00 RIFAXIMIN AND PROPRANOLOL COMBINATION
ABSTRACT THERAPY IS MORE EFFECTIVE THAN PROPRANOLOL
G05 MONOTHERAPY IN THE HEPATIC VENOUS PRESSURE
15:00 - 15:15 GRADIENT RESPONSE AND PROPRANOLOL DOSE
REDUCTION – A PILOT STUDY
ABSTRACT Soon Koo Baik, South Korea
G06
15:15 - 15:30 ENGINEERED HBV-SPECIFIC T CELLS: DISENTANGLING
ANTIVIRAL FROM KILLING CAPACITY
Sarene Koh, Singapore

EXOME SEQUENCING OF 243 LIVER TUMORS
IDENTIFIES NEW MUTATIONAL SIGNATURES AND
POTENTIAL THERAPEUTIC TARGETS
Kornelius Schulze, Germany

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED PHASE III TRIAL OF TSU-68
(ORANTINIB) COMBINED WITH TRANSCATHETER
ARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH
UNRESECTABLE HEPATOCELLULAR CARCINOMA
Joong-Won Park, South Korea

64 The International Liver Congress™ 2015 • ILC Programme